ArticleHepatology research : the official journal of the Japan Society of Hepatology2020
Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC.
Article in Hepatology research : the official journal of the Japan Society of Hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- [Rapid guideline for COVID-19 vaccination in patients with chronic liver diseases, hepatolbiliary malignancy and liver transplant].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021Guideline
- Article
- Spectrum of COVID-19 induced liver injury: A review report.World journal of hepatology · 2024Review
- Comprehensive analysis of the potential pathogenesis of COVID-19 infection and liver cancer.World journal of gastrointestinal oncology · 2024Article
- Screening, Surveillance, and Management of Hepatocellular Carcinoma During the COVID-19 Pandemic: a Narrative Review.Journal of gastrointestinal cancer · 2023Review
- Liver and Biliary Tract Disease in Patients with Coronavirus disease-2019 Infection.Gastroenterology clinics of North America · 2023Review
- Liver resection in a patient with persistent positive PCR test for coronavirus disease 2019 (COVID-19): a case report.Surgical case reports · 2022Article
- Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma.Journal of clinical medicine · 2022Review
- COVID-19 and liver diseases.Egyptian liver journal · 2022Review
- COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later.Journal of viral hepatitis · 2022Review
- Worldwide management of hepatocellular carcinoma during the COVID-19 pandemic.World journal of gastroenterology · 2021Review
- Assessing the impact of COVID-19 on liver cancer management (CERO-19).JHEP reports : innovation in hepatology · 2021Article
- Surgical treatment of hepatocellular carcinoma in the era of COVID-19 pandemic: A comprehensive review of current recommendations.World journal of clinical cases · 2021Review
- COVID-19 and comorbidities of hepatic diseases in a global perspective.World journal of gastroenterology · 2021Review
- COVID 19 and liver: An A-Z literature review.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2021Review
- Management of liver disease patients in different clinical situations during COVID-19 pandemic.Egyptian liver journal · 2021Review
- Potential Effects of Coronaviruses on the Liver: An Update.Frontiers in medicine · 2021Review
- Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC.Hepatology research : the official journal of the Japan Society of Hepatology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the coronavirus (COVID-19) pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVID-19 and the availability of resources, including personal protective equipment and inpatient beds). In addition, models suggest that the second and third waves of COVID-19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2-3 years). This guide should serve as a good reference for best practices in the management of HCC, which is in light of the possible risk of impending collapse of the healthcare system due to a surge in COVID-19 infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.